New Focus for Boehringer Ingelheim and Lilly Alliance
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance ®Alliance to focus combined expertise and investment to maximise Jardiance ®for people with type 2 diabetes, heart failure, and chronic kidney diseaseAlliance to continue to include three product families – empagliflozin, linagliptin and insulin glargine (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 4, 2019 Category: Research Source Type: news
cardiovascular-risk-factors
Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factorsPost-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin based on the number of cardiovascular risk factor goals achieved.1Findings from the post-hoc analysis were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes.1 This analysis suggests that, independent of the number of risk factor goals achieved, empagliflozin demonstrated card...
Source: Boehringer Ingelheim Corporate News - September 19, 2019 Category: Research Source Type: news
Empagliflozin in T2DM: long-term benefits at acceptable costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2019 Category: Drugs & Pharmacology Source Type: news
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need
FDA's Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 6.5 mi... Biopharmaceuticals, Cardiology, FDA Eli Lilly, Boehringer Ingelheim, empagliflozin, JARDIANCE, heart failure (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2019 Category: Pharmaceuticals Source Type: news
FDA-fast-track-designation-chronic-heart-failure
US FDA grants Fast Track designation to empagliflozin for the treatment of chronic heart failureFast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need. FDA ’s Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 26 million people affected by chronic heart failure worldwide, including 6.5 million in the US.1,2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 26, 2019 Category: Research Source Type: news
Effects of Empagliflozin on Metabolic Parameters in PCOS Effects of Empagliflozin on Metabolic Parameters in PCOS
In what ways might treatment with empagliflozin impact the metabolic parameters in women with PCOS?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
type-2-diabetes-cardiorenal-post-hoc-analysis
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuriaFindings from a post-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and chronic kidney disease without overt proteinuria were presented at the 79th American Diabetes Association Scientific Sessions® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 10, 2019 Category: Research Source Type: news
effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes
New post-hoc analysis of EMPA-REG OUTCOME ® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1 Cost effective analysis used modeling and simulations based on subgroup data from EMPA-REG OUTCOME ® to predict clinical events and estimated costs for people with type 2 diabetes and diabetic kidney disea...
Source: Boehringer Ingelheim Corporate News - April 14, 2019 Category: Research Source Type: news
EMPRISE real-world study results
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019 EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first two years of the study were presented at AMCP 2019 and ACC.191,2Initial results presented at AMCP 2019 showed empagliflozin was associated with reductions in all-cause hospitalisations compared with DPP-4 inhibitors, and significantly fewer recurrent emergency department visits and physician office visits1Initial re...
Source: Boehringer Ingelheim Corporate News - March 28, 2019 Category: Research Source Type: news
Empa ACC Expert Consensus Decision Pathway
American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news
Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes
EMPA-HEART Cardiolink-6 trial results suggest that the SGLT2 inhibitor is linked to reduced left ventricular mass, a surrogate for reduced heart failure, in patients with CVD and type 2 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
Study suggests diabetes medication improves heart structure
(St. Michael's Hospital) The diabetes medication empagliflozin has important effects that can improve cardiac structure in people with Type 2 diabetes who also have heart disease, suggests a new study led by St. Michael's Hospital. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2018 Category: International Medicine & Public Health Source Type: news
AHA: Reverse Remodeling Plays Role in Jardiance CV Benefit
(MedPage Today) -- Data show empagliflozin-associated LV remodeling (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - November 11, 2018 Category: Pediatrics Source Type: news
Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1Effect of empagliflozin on HHF was consistent in patients with and without established cardiovascular disease1Findings support data from the landmark EMPA-REG OUTCOME ® trial, in which empagliflozin reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news
Individual stress susceptibility and glucose metabolism are linked to brain function
(Johannes Gutenberg Universitaet Mainz) Researchers at the Department for Psychiatry and Psychotherapy at the Mainz University Medical Center and the German Resilience Center (DRZ) in Mainz have now discovered that stress-induced mental disturbances in mice are directly linked to abnormal glucose metabolism. Normalizing the stress-induced alterations in glucose levels, using the anti-diabetic drug empagliflozin, restored spatial memory as well as long-term glucose metabolism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2018 Category: International Medicine & Public Health Source Type: news
